European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes

被引：0
|
作者：
Bowen, D. [1 ]
Droste, J. [2 ]
Smith, A. [3 ]
Fenaux, P. [4 ]
Symeonidis, A. [5 ]
Sanz, G. [6 ]
Hellstrom-Lindberg, E. [7 ]
Cermak, J. [8 ]
Gologan, R. [9 ]
Germing, U. [10 ]
Stauder, R. [11 ]
Malcovati, L. [12 ]
de Witte, T. [2 ]
机构：
[1] Leeds Teaching Hosp, Leeds, W Yorkshire, England
[2] Univ Nijmegen, Nijmegen, Netherlands
[3] Univ York, York YO10 5DD, N Yorkshire, England
[4] Hop Avicenne, F-93009 Bobigny, France
[5] Univ Patras, GR-26110 Patras, Greece
[6] Hosp Univ La Fe, Valencia, Spain
[7] Karolinska Inst, Stockholm, Sweden
[8] Charles Univ Prague, Prague, Czech Republic
[9] Fundeni Clin Inst, Bucharest, Romania
[10] Univ Dusseldorf, Dusseldorf, Germany
[11] Innsbruck Med Univ, Innsbruck, Austria
[12] Univ Pavia, I-27100 Pavia, Italy
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70095-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [21] COSTEFFECTIVENESS OF AZACITIDINE FOR THE TREATMENT OF IPSS INT-2 OR HIGH-RISK MYELODYSPLASTIC SYNDROMES IN THE UK
    Brereton, N.
    Murthy, A.
    Akehurst, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 131 - 131
  • [22] Observational Study of Magnetic Resonance Imaging Monitoring in Patients with Aplastic Anemia (AA) and Low or Int-1 Risk of Myelodysplastic Syndromes(MDS) Complicated with Iron Overload
    Du, Yali
    Han, Bing
    Long, Zhangbiao
    Chen, Miao
    Hou, Bo
    Feng, Feng
    Wang, Zhao
    BLOOD, 2016, 128 (22)
  • [23] Quantitative Dynamics of Flow Cytometric Aberrancies during Treatment with Erythropoietin/G-CSF Are Predictive for Responses in LOW/INT-1 Risk Myelodysplastic Syndromes.
    Westers, Theresia M.
    Alhan, Canan
    Cali, Claudia
    Ossenkoppele, Gert J.
    de Loosdrecht, Arjan A. van
    BLOOD, 2008, 112 (11) : 586 - 586
  • [24] Correlation between WT1 expression level and the IPSS score in patients affected by myelodysplastic syndromes.
    Cilloni, D
    Messa, F
    Gottardi, E
    Fava, M
    Scaravaglio, P
    Bertini, M
    Girotto, M
    Marinone, C
    Ferrero, D
    Gallamini, A
    Levis, A
    Saglio, G
    BLOOD, 2002, 100 (11) : 375A - 376A
  • [25] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    HAEMATOLOGICA, 2017, 102 : 484 - 484
  • [26] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    LEUKEMIA RESEARCH, 2017, 55 : S29 - S30
  • [27] Flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group
    Westers, T. M.
    Kern, W.
    Ireland, R.
    Bene, M. C.
    Della Porta, M. G.
    Ogata, K.
    Van de Loosdrecht, A. A.
    LEUKEMIA RESEARCH, 2013, 37 : S45 - S45
  • [28] Flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group
    Zhijian, X.
    Tianjiao, Z.
    LEUKEMIA RESEARCH, 2013, 37 : S45 - S45
  • [29] EARLY TRANSFUSION PATTERNS PREDICT OUTCOMES INDEPENDENTLY OF IPSS-M SCORE IN MYELODYSPLASTIC SYNDROMES
    Creignou, M.
    Bernard, E.
    Crowther, M.
    Tranberg, A.
    Todisco, G.
    Moura, P.
    Ejerblad, E.
    Nilsson, L.
    Garelius, H.
    Antunovic, P.
    Lorenz, F.
    Rasmussen, B.
    Walldin, G.
    Mortera-Blanco, T.
    Jansson, M.
    Tobiasson, M.
    Edgren, G.
    Jadersten, M.
    Papaemmanuil, E.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2023, 128
  • [30] Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
    Fandrei, David
    Huynh, Tony
    Sebert, Marie
    Aguinaga, Lorea
    Bisio, Valeria
    Kim, Rathana
    Clappier, Emmanuelle
    Espeli, Marion
    Balabanian, Karl
    Moins-Teisserenc, Helene
    Toubert, Antoine
    Dulphy, Nicolas
    Fenaux, Pierre
    Ades, Lionel
    Zhao, Lin-Pierre
    BLOOD CANCER JOURNAL, 2023, 13 (01)
12345